Title |
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
|
---|---|
Published in |
Breast Cancer Research, September 2013
|
DOI | 10.1186/bcr3480 |
Pubmed ID | |
Authors |
Wenle Xia, Emanual F Petricoin, Sumin Zhao, Leihua Liu, Takuya Osada, Qing Cheng, Julia D Wulfkuhle, William R Gwin, Xiaoyi Yang, Rosa I Gallagher, Sarah Bacus, H Kim Lyerly, Neil L Spector |
Abstract |
The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted tumors. Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not been durable. Consequently, elucidation of mechanisms of acquired therapeutic resistance to HER-directed therapies is of critical importance. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 1% |
United Kingdom | 1 | <1% |
Unknown | 214 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 61 | 28% |
Student > Ph. D. Student | 22 | 10% |
Researcher | 22 | 10% |
Student > Master | 9 | 4% |
Student > Doctoral Student | 5 | 2% |
Other | 10 | 5% |
Unknown | 89 | 41% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 41 | 19% |
Biochemistry, Genetics and Molecular Biology | 33 | 15% |
Agricultural and Biological Sciences | 28 | 13% |
Medicine and Dentistry | 15 | 7% |
Chemistry | 3 | 1% |
Other | 6 | 3% |
Unknown | 92 | 42% |